CIRM Funded Clinical Trials
Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative)
Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that occurs when fluid leaks into the lungs. As a result, breathing becomes difficult and oxygen cannot get into the body. ARDS is one of the most serious and lethal consequence of COVID-19.
This clinical trial will use Mesenchymal Stromal Cells (MSCs) for the treatment of ARDS, including both COVID-19 positive and COVID-19 negative patients, with the hopes of improving oxygenation.
Phase 2B trial
Test safety and efficacy.